ArticleNature2019
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 914 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
914citing papers in PubMed, 1 pooled it
58.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data
NCT06224049 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma
Who cites it
914 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,391 citations in OpenAlex.
- Efficacy and Safety of EGF/EGFR Vaccines in EGFR-Driven Solid Tumors: A Systematic Review and Meta-Analysis of Controlled and Single-Arm Studies.Cancer medicine · 2025Pooled it
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nature medicine · 2026Trial
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- The 15-year bibliometric landscape of glioblastoma vaccines: Emergence of combinatorial immunotherapy.Human vaccines & immunotherapeutics · 2026Review
- Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.Future science OA · 2026Review
- Toward next-generation therapeutic HPV vaccines: A review on expanding the antigen repertoire and an integrated bioinformatics selection framework.Human vaccines & immunotherapeutics · 2026Review
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- Abundant CD8British journal of cancer · 2026Article
- Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives.Journal of personalized medicine · 2026Review
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- Artificial intelligence for translational personalized neoantigen cancer vaccine development.Journal of biomedical science · 2026Review
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma.International journal of radiation oncology, biology, physics · 2026Review
854 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
51 authors at 9 institutions in 3 countries.
Derin B Keskin *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Annabelle J Anandappa *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jing Sun *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Itay Tirosh *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nathan D Mathewson *Harvard Medical School, Boston, MA, USA.
Shuqiang LiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anita Giobbie-HurderDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kristen FeltCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Evisa GjiniCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sachet A ShuklaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zhuting HuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Letitia LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Phuong M LeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rosa L AllesøeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alyssa R RichmanBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Monika S KowalczykBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Sara AbdelrahmanCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jack E GeduldigDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah CharbonneauDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kristine PeltonDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
J Bryan IorgulescuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Liudmila ElaginaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Wandi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Oriol OliveDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christine McCluskeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lars R OlsenDepartment of Bio- and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.
Jonathan StevensDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
William J LaneHarvard Medical School, Boston, MA, USA.
Andres M SalazarOncovir Inc, Washington, DC, USA.
Heather DaleyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick Y WenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
E Antonio ChioccaHarvard Medical School, Boston, MA, USA.
Maegan HardenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Niall J LennonBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Stacey GabrielBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Eric S LanderBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Aviv RegevBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Donna NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott J RodigHarvard Medical School, Boston, MA, USA.
Keith L LigonBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Mario L SuvàBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kai W WucherpfennigHarvard Medical School, Boston, MA, USA.
Nir HacohenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Edward F FritschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David A ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_reardon@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USBrigham and Women's Hospital · USHarvard University · USCenter for Cancer Research · USMassachusetts General Hospital · USOncovir (United States) · USTechnical University of Denmark · DKWeizmann Institute of Science · IL
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MTargeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WENDY Beth LONDON · 2013 to 2026
$33.5MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0MVASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MMerkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapyR01CA279391 · NCI · DANA-FARBER CANCER INST · PI Derin B Keskin · 2024 to 2026
$2.2MPost-transplant vaccines to enhance graft-versus-leukemia responsesR01HL103532 · NHLBI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2010 to 2013
$1.7MImmunogenomic analytical approaches for research and clinical applicationsR50CA211482 · NCI · DANA-FARBER CANCER INST · PI SHUKLA, SACHET ASHOK · 2016 to 2020
$1.3MPhysical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccinesR21CA216772 · NCI · DANA-FARBER CANCER INST · PI KESKIN, DERIN B · 2018 to 2019
$420kHoward Hughes Medical InstituteNCI NIH HHS 1R01CA155010-02NCI NIH HHS 2P50CA101942-11A1NCI NIH HHS P01 CA163205NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA279391NCI NIH HHS R21 CA216772NCI NIH HHS R21 CA216772-01A1NCI NIH HHS R50 CA211482NCI NIH HHS T32 CA207021NHLBI NIH HHS 5R01HL103532-03NHLBI NIH HHS R01 HL103532NHLBI NIH HHS T32 HL007627
Abstract
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses
Indexed as
AdultAgedAntigens, NeoplasmCancer VaccinesDexamethasoneDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGlioblastomaHumansMiddle AgedPromoter Regions, GeneticReceptors, Antigen, T-CellT-LymphocytesTumor Suppressor ProteinsYoung AdultAntigens, NeoplasmCancer VaccinesDexamethasoneDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanReceptors, Antigen, T-CellTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04792437ClinicalTrials.gov
NCT06224049ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.